Acute Myeloid Leukemia, Pediatric
Conditions
Brief summary
The investigators adopted the CAMS（Chinese Academy of Medical Sciences）-2009 trial for pediatric acute myeloid leukemia (AML) patients between 2009 to 2015, in which a risk-stratified strategy and dose-dense intensive chemotherapy were introduced. The outcomes of CAMS-2009 trial were retrospectively analyzed, and compared to the CAMS-2005 trial.
Interventions
OTHERRisk-stratified therapy
Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Months to 16 Years
Healthy volunteers
No
Inclusion criteria
* newly diagnosed AML
Exclusion criteria
* children with Down's syndrome and acute promyelocytic leukemia (APL)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall survival (OS) | From date of diagnosed until the date of death from any cause, assessed up to 60 months | overall survival |
| event-free survival (EFS) | From date of diagnosed until the date of first relapse or date of death from any cause, whichever came first, assessed up to 60 months | event-free survival |
| complete remission (CR) | through study completion, an average of 1 year | fewer than 5% blast cells in the bone marrow aspirate and the absence of extramedullary involvement (EMI) |
Countries
China
Contacts
STUDY_CHAIRZhu Xiaofan
Institute of Hematology & Blood Disease Hospital
Outcome results
None listed